JP6785838B2 - 新規な置換グリシン誘導のｆｘｉａ阻害剤 - Google Patents
新規な置換グリシン誘導のｆｘｉａ阻害剤 Download PDFInfo
- Publication number
- JP6785838B2 JP6785838B2 JP2018505695A JP2018505695A JP6785838B2 JP 6785838 B2 JP6785838 B2 JP 6785838B2 JP 2018505695 A JP2018505695 A JP 2018505695A JP 2018505695 A JP2018505695 A JP 2018505695A JP 6785838 B2 JP6785838 B2 JP 6785838B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- substituted
- phenyl
- triazole
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(C(N(*)*)=O)N(CCC(c1c(*)c(*)ccc1*)=C1)C1=O Chemical compound *C(C(N(*)*)=O)N(CCC(c1c(*)c(*)ccc1*)=C1)C1=O 0.000 description 5
- ADFSKORFEVWHPA-UHFFFAOYSA-N CC(C)(C)OC(C(Cc1ccccc1)N(CCC(c(c(C#N)ccc1Cl)c1F)=C1)C1=O)=O Chemical compound CC(C)(C)OC(C(Cc1ccccc1)N(CCC(c(c(C#N)ccc1Cl)c1F)=C1)C1=O)=O ADFSKORFEVWHPA-UHFFFAOYSA-N 0.000 description 1
- GVJZHGCVSYBPIM-UHFFFAOYSA-N CC1(C)OB(c(cc(cc2)Cl)c2N)OC1(C)C Chemical compound CC1(C)OB(c(cc(cc2)Cl)c2N)OC1(C)C GVJZHGCVSYBPIM-UHFFFAOYSA-N 0.000 description 1
- ISTPGKLEXXCRAX-UHFFFAOYSA-N COc1ncnc(-c(cc(cc2)Cl)c2-[n]2nnc([Si+](C)(C)C)c2)c1 Chemical compound COc1ncnc(-c(cc(cc2)Cl)c2-[n]2nnc([Si+](C)(C)C)c2)c1 ISTPGKLEXXCRAX-UHFFFAOYSA-N 0.000 description 1
- FYIBSPOZBMRQCX-UHFFFAOYSA-N N#Cc(c(C(CCN1C(Cc2ccccc2)C(O)=O)=CC1=O)c1F)ccc1Cl Chemical compound N#Cc(c(C(CCN1C(Cc2ccccc2)C(O)=O)=CC1=O)c1F)ccc1Cl FYIBSPOZBMRQCX-UHFFFAOYSA-N 0.000 description 1
- ALICLAPWNCQXFR-AWEZNQCLSA-N NN[C@@H](Cc1ccccc1)C(Nc(cc1)ccc1C(O)=O)=O Chemical compound NN[C@@H](Cc1ccccc1)C(Nc(cc1)ccc1C(O)=O)=O ALICLAPWNCQXFR-AWEZNQCLSA-N 0.000 description 1
- BUYKUSRHEDJMJM-UHFFFAOYSA-N Nc(cc1)c(C=O)c(F)c1Cl Chemical compound Nc(cc1)c(C=O)c(F)c1Cl BUYKUSRHEDJMJM-UHFFFAOYSA-N 0.000 description 1
- YMGGSGUQDWLEOT-UHFFFAOYSA-N O=C(C(F)(F)F)Nc(cc1F)ccc1Cl Chemical compound O=C(C(F)(F)F)Nc(cc1F)ccc1Cl YMGGSGUQDWLEOT-UHFFFAOYSA-N 0.000 description 1
- WUSYBOIPODFQGR-VWLOTQADSA-N OC(c(cc1)ccc1NC([C@H](Cc(cc1)ccc1NC(C1CC1)=O)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)=O)=O Chemical compound OC(c(cc1)ccc1NC([C@H](Cc(cc1)ccc1NC(C1CC1)=O)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)=O)=O WUSYBOIPODFQGR-VWLOTQADSA-N 0.000 description 1
- XPWJZYMWMNAWGL-DEOSSOPVSA-N OC(c(cc1)ccc1NC([C@H](Cc1ccccc1)N(CCC(c(c(-[n]1nncc1)ccc1Cl)c1F)=C1)C1=O)=O)=O Chemical compound OC(c(cc1)ccc1NC([C@H](Cc1ccccc1)N(CCC(c(c(-[n]1nncc1)ccc1Cl)c1F)=C1)C1=O)=O)=O XPWJZYMWMNAWGL-DEOSSOPVSA-N 0.000 description 1
- ARNZYRBXMAGCIZ-UHFFFAOYSA-N Oc1ncnc(-c2cc(Cl)ccc2-[n]2nnc(C(F)(F)F)c2)c1 Chemical compound Oc1ncnc(-c2cc(Cl)ccc2-[n]2nnc(C(F)(F)F)c2)c1 ARNZYRBXMAGCIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201267P | 2015-08-05 | 2015-08-05 | |
| US62/201,267 | 2015-08-05 | ||
| PCT/US2016/045276 WO2017023992A1 (en) | 2015-08-05 | 2016-08-03 | Novel substituted glycine derived fxia inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522046A JP2018522046A (ja) | 2018-08-09 |
| JP2018522046A5 JP2018522046A5 (enExample) | 2019-09-12 |
| JP6785838B2 true JP6785838B2 (ja) | 2020-11-18 |
Family
ID=56618292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505695A Active JP6785838B2 (ja) | 2015-08-05 | 2016-08-03 | 新規な置換グリシン誘導のｆｘｉａ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10336730B2 (enExample) |
| EP (1) | EP3331872B1 (enExample) |
| JP (1) | JP6785838B2 (enExample) |
| KR (1) | KR102697816B1 (enExample) |
| CN (1) | CN108137549B (enExample) |
| ES (1) | ES2754599T3 (enExample) |
| WO (1) | WO2017023992A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2762987T3 (es) | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| KR102086934B1 (ko) | 2015-07-29 | 2020-03-09 | 브리스톨-마이어스 스큅 컴퍼니 | 알킬 또는 시클로알킬 P2' 모이어티를 갖는 인자 XIa 마크로시클릭 억제제 |
| ES2871111T3 (es) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
| JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 新規な置換グリシン誘導のｆｘｉａ阻害剤 |
| JP7112715B2 (ja) * | 2018-03-23 | 2022-08-04 | 株式会社Kyulux | 有機発光素子材料合成用原料および化合物 |
| CN112004810B (zh) | 2018-07-02 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
| KR20210033953A (ko) * | 2018-07-19 | 2021-03-29 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 응고 인자 xia 억제제 및 이의 중간체의 제조 방법 |
| KR20210105939A (ko) * | 2018-12-17 | 2021-08-27 | 바이엘 악티엔게젤샤프트 | 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체 |
| CN112047931B (zh) * | 2019-06-06 | 2024-03-08 | 上海美悦生物科技发展有限公司 | FXIa凝血因子抑制剂、其药物组合物和用途 |
| CN112341377B (zh) * | 2019-08-09 | 2024-05-14 | 上海美悦生物科技发展有限公司 | 一种杂环类化合物及其应用 |
| MX2022003649A (es) | 2019-09-27 | 2022-06-08 | Shenzhen Salubris Pharm Co Ltd | Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos. |
| CN113005176A (zh) * | 2019-12-20 | 2021-06-22 | 深圳市帝迈生物技术有限公司 | 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒 |
| CA3189771A1 (en) * | 2020-07-22 | 2022-01-27 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
| WO2022057849A1 (zh) * | 2020-09-17 | 2022-03-24 | 浙江海正药业股份有限公司 | 哌嗪类衍生物及其制备方法和用途 |
| WO2022083707A1 (zh) * | 2020-10-23 | 2022-04-28 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物或其盐的医药用途 |
| TW202222315A (zh) * | 2020-10-23 | 2022-06-16 | 大陸商深圳信立泰藥業股份有限公司 | ＦＸＩａ抑制劑化合物的鹽、包括其的藥物組合物及其用途 |
| CN112679446A (zh) * | 2020-10-26 | 2021-04-20 | 都创(上海)医药科技有限公司 | 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法 |
| WO2022122035A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海领泰生物医药科技有限公司 | 凝血因子XIa抑制剂及其制备方法和应用 |
| CN112675173B (zh) * | 2020-12-25 | 2022-04-05 | 华南理工大学 | FXIa抑制剂化合物或其盐的医药用途 |
| WO2022194225A1 (zh) * | 2021-03-18 | 2022-09-22 | 深圳信立泰药业股份有限公司 | FXIa抑制剂化合物杂质及其制备方法和用途FXIa抑制剂化合物杂质及其制备方法和用途 |
| CN116283750B (zh) * | 2021-09-09 | 2025-02-07 | 成都泰和伟业生物科技有限公司 | 一种杂环酰胺类衍生物及其制备方法和用途 |
| CN116199672A (zh) * | 2021-11-30 | 2023-06-02 | 成都泰和伟业生物科技有限公司 | 一种嘧啶酰胺类衍生物及其制备方法和用途 |
| CN116262740A (zh) * | 2022-11-18 | 2023-06-16 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| CN119894901A (zh) | 2023-06-30 | 2025-04-25 | 深圳信立泰药业股份有限公司 | 一种多取代的大环化合物及其制备方法与应用 |
| CN117164563B (zh) * | 2023-09-07 | 2025-06-10 | 成都施贝康生物医药科技有限公司 | 氧代嘧啶类化合物及其制备方法和用途 |
| CN117164562B (zh) * | 2023-09-07 | 2025-06-13 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117164566B (zh) * | 2023-09-07 | 2025-06-06 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117164564B (zh) * | 2023-09-07 | 2025-07-08 | 成都施贝康生物医药科技有限公司 | 氧代哒嗪类化合物及其制备方法和用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3900483A (en) * | 1972-04-15 | 1975-08-19 | Konishiroku Photo Ind | ' -(2(1h)pyridone)+65 -pivalyl-5-(' -2,4-di-t-amyl-phenoxybutyramide)-acetanilides and derivatives |
| US4008086A (en) * | 1972-04-15 | 1977-02-15 | Konishiroku Photo Industry Co., Ltd. | Silver halide emulsion containing photographic yellow coupler |
| DE2960194D1 (en) | 1978-05-08 | 1981-04-16 | Ucb Sa | Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| WO1982000402A1 (en) | 1980-08-07 | 1982-02-18 | Shamrock Corp Diamond | Herbicidal and plant growth regulant diphenylpyridazinones |
| WO1997027200A1 (en) | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| CA2383008A1 (en) | 1999-06-14 | 2000-12-21 | Amanda Jane Lyons | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| CN110894196A (zh) | 2001-09-21 | 2020-03-20 | 百时美-施贵宝控股爱尔兰无限公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| CA2506114A1 (en) | 2002-12-05 | 2004-06-24 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
| WO2004058728A1 (ja) | 2002-12-24 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | 新規なエチレンジアミン誘導体 |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| WO2005061462A2 (en) | 2003-12-19 | 2005-07-07 | Neurogen Corporation | Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators |
| WO2006090234A1 (en) | 2005-02-22 | 2006-08-31 | Ranbaxy Laboratories Limited | Heterocyclic derivatives as cell adhesion inhibitors |
| WO2007081570A2 (en) | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
| TW200829171A (en) | 2006-11-17 | 2008-07-16 | Nihon Nohyaku Co Ltd | Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof |
| US8048886B2 (en) | 2006-12-07 | 2011-11-01 | Novartis Ag | Substituted pyrazine-3-one-derivatives as IAP inhibitors |
| CA2678577A1 (en) | 2007-02-26 | 2008-09-04 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| WO2009078498A1 (en) | 2007-12-17 | 2009-06-25 | Green Cross Corporation | Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands |
| US8598160B2 (en) | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| TW200944506A (en) | 2008-03-26 | 2009-11-01 | Takeda Pharmaceutical | Substituted pyrazole derivatives and use thereof |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| US8293917B2 (en) | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
| WO2010111059A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| JP2010280638A (ja) | 2009-06-08 | 2010-12-16 | Nippon Nohyaku Co Ltd | ハロアルキルスルホンアニリド誘導体又はその塩類及びこれを有効成分とする除草剤並びにその使用方法 |
| US9409918B2 (en) | 2009-10-29 | 2016-08-09 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
| IN2014CN02805A (enExample) * | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| CN104136431B (zh) | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
| US9409908B2 (en) * | 2012-08-03 | 2016-08-09 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor XIa inhibitors |
| JP6360500B2 (ja) | 2013-02-06 | 2018-07-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 骨関節炎の処置のためのアグリカナーゼ阻害剤としての置換カルボン酸誘導体 |
| WO2014160592A2 (en) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 新規な置換グリシン誘導のｆｘｉａ阻害剤 |
-
2016
- 2016-08-03 JP JP2018505695A patent/JP6785838B2/ja active Active
- 2016-08-03 WO PCT/US2016/045276 patent/WO2017023992A1/en not_active Ceased
- 2016-08-03 KR KR1020187005764A patent/KR102697816B1/ko active Active
- 2016-08-03 CN CN201680058331.8A patent/CN108137549B/zh active Active
- 2016-08-03 US US15/750,212 patent/US10336730B2/en active Active
- 2016-08-03 EP EP16750350.7A patent/EP3331872B1/en active Active
- 2016-08-03 ES ES16750350T patent/ES2754599T3/es active Active
-
2019
- 2019-06-27 US US16/454,848 patent/US10899743B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180222889A1 (en) | 2018-08-09 |
| EP3331872B1 (en) | 2019-09-25 |
| JP2018522046A (ja) | 2018-08-09 |
| US10899743B2 (en) | 2021-01-26 |
| EP3331872A1 (en) | 2018-06-13 |
| CN108137549A (zh) | 2018-06-08 |
| US20190382378A1 (en) | 2019-12-19 |
| CN108137549B (zh) | 2021-07-20 |
| KR102697816B1 (ko) | 2024-08-21 |
| KR20180031037A (ko) | 2018-03-27 |
| ES2754599T3 (es) | 2020-04-20 |
| WO2017023992A1 (en) | 2017-02-09 |
| US10336730B2 (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6785838B2 (ja) | 新規な置換グリシン誘導のｆｘｉａ阻害剤 | |
| JP6937734B2 (ja) | 第ｘｉａ因子阻害剤としてのピリミジノン | |
| JP6630004B2 (ja) | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 | |
| JP6419836B2 (ja) | ヘテロサイクルと縮合した大環状第ｘｉａ因子阻害剤 | |
| JP6082463B2 (ja) | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ | |
| JP6742348B2 (ja) | 第ｘｉａ因子阻害剤としてのジアミド大員環 | |
| JP6629958B2 (ja) | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 | |
| JP6816103B2 (ja) | 非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤 | |
| BR112017006702B1 (pt) | Pirimidinonas inibidoras de fator xia, composição farmacêutica e seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190731 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190731 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200918 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201027 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6785838 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |